The Purpose of This Clinical Study is to Evaluate Optimized Maximum Plus for Maximum Visual Acuity (MPMVA) Refractive Technique and Its Effect on Visual Performance.

Clinical Evaluation of Visual Outcomes in LEAP, HIGH, COMP and VISN Extension Cohort

This is a prospective, multicenter, parallel groups, non-interventional, examiner masked, comparative clinical study. Patients that participated in previous Hoya studies, and patients previous implanted with Hoya non-toric monofocal IOLs (sub-study only) will be enrolled in the study. The sample size for this study is based on demonstrating the non-inferiority of the mean distance-corrected intermediate visual acuity (DCIVA) in Group 1 (Site 1) compared with Group 2 (Site 2).

Inclusion Criteria:

Main study:

1. Previously implanted with intraocular lens through 2 previous IOL studies;
2. Clear intraocular media with no clinically significant opacity, in the investigator's judgment, that would affect visual acuity;
3. Able to provide informed consent and complete all required study procedures.

Exploratory sub-study:

1. Additional inclusion criteria: Pseudophakic eyes implanted with one of the IOLs in one eye from 3 previous IOL studies

Exclusion Criteria:

Main study:

1. Corrected distance visual acuity (CDVA) worse than 0.2 logMAR (or 20/32 Snellen)
2. Subjects with ongoing medical conditions or treatment that might impact outcomes during the study visit as determined by the investigator.

Exploratory sub-study:

1. Additional exclusion criteria: Pseudophakic eyes with oblique residual astigmatism.